| Kevin Gerard Moser, | |
|
2802 Papermill Rd, Wyomissing, PA 19610-1065 | |
| (484) 628-2388 | |
| Not Available |
| Full Name | Kevin Gerard Moser |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 8 Years |
| Location | 2802 Papermill Rd, Wyomissing, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235583469 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | MD469643 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tower Health At Home - Berks | Wyomissing, PA | Home health agency |
| Reading Hospital | West reading, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tower Health Medical Group | 7618889213 | 577 |
News Archive
Researchers in the United States, UK, and Canada have published a commentary challenging the suggestion that the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may not be airborne.
Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.
Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.
The European Society for Medical Oncology (ESMO) is calling on European politicians to voice their support for a decisive step to help ensure cancer patients receive the best possible treatment.
› Verified 6 days ago
| Entity Name | Tower Health Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609291350 PECOS PAC ID: 7618889213 Enrollment ID: O20040311000072 |
News Archive
Researchers in the United States, UK, and Canada have published a commentary challenging the suggestion that the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may not be airborne.
Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.
Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.
The European Society for Medical Oncology (ESMO) is calling on European politicians to voice their support for a decisive step to help ensure cancer patients receive the best possible treatment.
› Verified 6 days ago
| Entity Name | Morganstein De Falcis Rehabilitation Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235124892 PECOS PAC ID: 4587614789 Enrollment ID: O20050126000094 |
News Archive
Researchers in the United States, UK, and Canada have published a commentary challenging the suggestion that the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may not be airborne.
Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.
Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.
The European Society for Medical Oncology (ESMO) is calling on European politicians to voice their support for a decisive step to help ensure cancer patients receive the best possible treatment.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin Gerard Moser, 2802 Papermill Rd, Wyomissing, PA 19610-1065 Ph: (484) 334-7026 | Kevin Gerard Moser, 2802 Papermill Rd, Wyomissing, PA 19610-1065 Ph: (484) 628-2388 |
News Archive
Researchers in the United States, UK, and Canada have published a commentary challenging the suggestion that the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may not be airborne.
Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.
Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.
The European Society for Medical Oncology (ESMO) is calling on European politicians to voice their support for a decisive step to help ensure cancer patients receive the best possible treatment.
› Verified 6 days ago
Somkiat Hemtasilpa, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2802 Papermill Rd, Wyomissing, PA 19610 Phone: 484-628-2778 Fax: 484-628-2688 | |
Haiping Mei, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2802 Papermill Rd, Wyomissing, PA 19610 Phone: 484-628-2778 Fax: 484-628-2688 | |
Mary J Elmer, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2201 Ridgewood Rd, Wyomissing, PA 19610 Phone: 610-736-0182 | |
Sanghoon Kim, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2802 Papermill Rd, Wyomissing, PA 19610 Phone: 484-628-2778 Fax: 484-388-2688 | |
Li-hong Lu, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2802 Papermill Rd, Wyomissing, PA 19610 Phone: 484-628-2778 Fax: 484-628-2688 | |
Mr. Kraig William Leiby, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1350 Broadcasting Rd, Ste 201, Wyomissing, PA 19610 Phone: 610-685-9600 Fax: 610-685-6700 |